ACURATE neo2 Aortic Valve System Shows Mixed Results in Aortic Stenosis Trial
核心洞察
The ACURATE IDE trial assessed the ACURATE neo2 valve against standard valves for severe aortic stenosis (搜索), revealing a higher composite rate of mortality, stroke, or rehospitalization.
Post-hoc analysis identified that approximately 20% of ACURATE neo2 valves were under-expanded, impacting overall outcomes and suggesting the importance of procedural optimization.
Boston Scientific is working with the FDA on regulatory strategy for ACURATE valve platform approval in the U.S. and plans further studies on improved implantation techniques.
Boston Scientific's ACURATE neo2 Aortic Valve System (搜索), a second-generation transcatheter aortic valve replacement (TAVR) technology, demonstrated mixed outcomes in the ACURATE IDE clinical trial. The trial, presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024, evaluated the system's efficacy in treating patients with severe, symptomatic aortic stenosis (搜索) across various surgical risk levels.
The randomized trial compared the ACURATE neo2 valve against a control group receiving either the SAPIEN valve (搜索) or the Evolut transcatheter aortic valve system (搜索), chosen at the physician's discretion. The primary endpoint, a composite of all-cause mortality, stroke, or rehospitalization at one year, occurred in 16.16% of patients in the ACURATE neo2 arm versus 9.53% in the control arm. This difference did not meet the pre-specified criterion for non-inferiority (posterior probability for non-inferiority was 77.9%, below the 97.5% threshold).
Procedural Optimization Insights
A post-hoc analysis of the ACURATE IDE trial identified that approximately 20% of implanted ACURATE neo2 valves were under-expanded. This assessment involved reviewing key procedural factors, including pre- and post-dilation techniques crucial for proper valve expansion. The data indicated that the rate of death, stroke, or rehospitalization at one year was similar between the expanded ACURATE neo2 group and the control group.
"This trial is the largest randomized comparison of TAVR platforms and was conducted over four years, including during a global pandemic that introduced complexities for enrollment," said Michael Reardon, M.D., professor of cardiothoracic surgery at Houston Methodist DeBakey Heart & Vascular Center and co-principal investigator of the ACURATE IDE trial. "These data add to the breadth of clinical knowledge of the ACURATE valve platform and provide compelling insights on the importance of procedural optimization that will be beneficial for TAVR moving forward."
Implications for TAVR
The findings suggest that optimizing valve expansion during TAVR procedures is critical for improving patient outcomes. Boston Scientific is actively collaborating with the U.S. Food and Drug Administration (FDA) regarding the regulatory pathway for the ACURATE valve platform in the U.S. Further studies are planned to investigate improved implantation techniques to mitigate valve under-expansion.
"The data presented today give clinicians a greater understanding of the impact of procedural optimization as the TAVR space continues to rapidly evolve," said Janar Sathananthan, M.D., chief medical officer, Interventional Cardiology Therapies, Boston Scientific. "We believe the findings from the ACURATE IDE post-hoc analysis and implementation of steps to mitigate valve under-expansion may improve outcomes for the ACURATE valve and have important implications on other commercially available TAVR valves, and we look forward to studying these improved techniques in future trials of the device."